PROJECT

Projects

Environmental & Social Review Summary

Project Number

45541

Company Name

DI'AN DIAGNOSTICS GROUP CO., LTD.

Date ESRS Disclosed

Oct 11, 2021

Country

China

Region

East Asia and the Pacific

Last Updated Date

Jun 11, 2022

Environmental Category

B - Limited

Status

Active

Previous Events

Approved : Jan 18, 2022
Signed : Jan 20, 2022
Invested : May 11, 2022

Sector

other

Industry

other

Department

Regional Industry - MAS Asia & Pac

Project Description

The proposed investment is a long-term corporate loan of up to US$150 million to Di’An Diagnostics Group Co. Ltd., (“Di’An Diagnostics”, “Di’An”, or the “company”), one of the largest third-party diagnostic services and product providers in China with ~40 laboratories across China serving more than 20,000 medical institutions, and which is publicly listed on the Shenzhen Stock Exchange (300244). Under the proposed use of proceeds, Di’An will: (i) add up to five new diagnostic centers to its independent clinical laboratory (ICL) network including associated cold chain warehouses; (ii) expand existing ICLs including upgrading of equipment; (iii) expand its self-developed In Vitro Diagnostic (IVD) production capacity, (iv) expand its research and development operations; and (v) build advanced IT infrastructure and data analytics functions over the next five years (together, the “Project”). Project locations will mostly be in the major provincial capitals of China. The additional IVD production capacity will mainly focus on advanced diagnostic fields of application, such as mass spectrometry, molecular diagnostics, and micronutrient diagnostics.

Di’An Diagnostics Group Co., Ltd. (http://www.dazd.cn/) is located in Hangzhou, Zhejiang, China. Dian Diagnostics Group Co., Ltd. has 9,300 total employees across all of its locations and generated $1.65 billion in sales (USD) by the end of 2020. There are 147 companies in the Dian Diagnostics Group Co., Ltd. corporate family. Most Di’An Diagnostics laboratories and manufacturing facilities are located within industrial parks, with limited exposure to local communities as such parks are typically set up at considerable distances from local residences and sensitive E&S receptor areas.

Overview of IFC's Scope of Review

IFC’s review of this proposed investment consisted of appraising environmental, health, safety, and social (EHSS) information provided by Di’An Diagnostics including: (i) company’s corporate environmental, health, and safety (EHS) policies and procedures; (ii) Human Resources (HR) policies and employee manual; (iii) sample environmental impact assessment (EIA) reports and EHS operational records of the company’s ICL and IVD production facilities. The appraisal included in-depth discussions with the company’s senior management and corporate and facility level personnel responsible for EHS, HR management, administrative and facility management functions, and other operational staff via video conferencing on 29 July 2021, as well as a site visit to a Di’An ICL in Beijing on August 20, 2021, and virtual (video) site visits to the following facilities: the Di’An Diagnostics IVD reagent production base in Yuhang (on August 20, 2021), a Di’An Hangzhou testing center (same date), and a Di’An reagent production center in the Hangzhou area on August 24, 2021.

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan